Click here to view the January 2022 edition of Dates for Your Diary
News
SAN FRANCISCO, Jan. 19, 2022 /PRNewswire/ -- Altos Labs™ (Altos™) launched today as a new biotechnology company dedicated to unraveling the deep biology of cellular rejuvenation programming. Altos' mission is to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. The company launches with a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission.
WILMINGTON, Mass. & BOSTON--(BUSINESS WIRE)--Jan. 19, 2022-- Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, LLC (“Valo”), the technology company using human-centric data and computation powered by artificial intelligence (AI) to transform the drug discovery and development process, today announced the formation of a multiyear strategic partnership.
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP
First patient dosed in potential game-changing diabetes combination therapy
At a glance:
We would like to invite you to participate in the SLAS Mentor Match program. SLAS is committed to transforming life sciences through research. We are an international professional society of academic, industry and government researchers as well as developers and providers of laboratory automation tools. The SLAS mentor program was developed to encourage experienced professionals (mentors) in our diverse community to pass on their knowledge and experience to young professionals (mentees).
The agreement will facilitate understanding of complex relationships between microbiome, food and other factors, including potential causes of health and disease
Shenzhen, China and Cambridge, UK, 11 January, 2022: NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development company in China, and PhoreMost Limited (PhoreMost), the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, today announced an oncology drug discovery research collaboration.
Cambridge, UK - 12 January 2022 – Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator empowering life science researchers with high-quality biological reagents and tools critical to research, drug discovery and diagnostics, today received the Employees’ Choice Award 2022 recognizing Abcam in Glassdoor’s Best Places to Work in the UK. Abcam is the first biotech company to be ranked in the top five for two years in a row (1).